One of the newest forms of vaccines is mRNA-based vaccines, which enable cells in the body to create specific proteins that trigger an immune response and build antibodies against a specific sickness.
mRNA-based immunizations for preventing SARS-CoV-2 have gained a lot of attention among healthcare stakeholders due to its underlying advantages. Only a few of the advantages include high efficacy, safety, and reliability, as well as the potential to protect patients against infections produced by new SARS-CoV-2 mutant strains.
According to BIS Research, the global mRNA vaccines and therapeutics market for COVID-19 vaccines is estimated to reach $28.92 billion in 2025, up from $51.65 billion in 2021, with a CAGR of -13.50 percent between 2021 and 2025.
The global mRNA vaccines and therapeutics market based on non-COVID-19 vaccines is predicted to grow at a CAGR of 96.49 percent between 2026 and 2031, from $0.05 billion in 2026 to $1.69 billion in 2031.
The non-COVID-19 vaccine market is growing due to an increased focus on R&D for the development of mRNA-based vaccines and therapeutics for non-COVID-19 applications, increased funding, the growing prominence of mRNA-based treatment modalities, and an increased emphasis on the adoption of targeted therapeutics for rare diseases and cancer.
Factors Influencing mRNA Vaccines Market Growth
Several factors influence the global market for mRNA vaccines and therapeutics, including those that both promote and constrain market growth.
Growing COVID-19 cases throughout the globe, a favorable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines are all factors driving the industry forward.
With the rise of COVID-19 cases, there is a compelling need for effective and efficient vaccines, which might be fulfilled by encouraging vaccine development. Despite the fact that a number of COVID-19 vaccines have been produced, including inactivated vaccines, live-attenuated vaccines, and viral vector vaccines, mRNA-based vaccines are viewed as the most promising owing to their advantages. In COVID-19 patients, mRNA-based COVID-19 vaccinations increase protein translation, innate regulation, and adaptive immunogenicity.
Furthermore, demand for mRNA-based COVID-19 vaccines is surpassing availability due to an increase in COVID-19 cases throughout the world. Regulatory agencies all across the world have abolished the restrictions on these immunizations. Regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are offering emergency use authorizations (EMAs) and conditional marketing authorizations (CMAs) to companies producing mRNA-based COVID-19 vaccines to ensure a constant supply for ongoing vaccination strategies.
Furthermore, as a consequence of the worldwide surge in COVID-19 cases and many national governments taking significant efforts to limit the spread of SARS-CoV-2 and lessen its impact, there has been a significant increase in funding for vaccine development.
The market’s growth is being hampered by logistical challenges with mRNA-based COVID-19 vaccines, as well as the high cost of mRNA-based COVID-19 vaccines.
Despite the benefits, there are practical problems concerning the availability of mRNA-based COVID-19 vaccines in underdeveloped countries, which are delaying the vaccine’s adoption. Furthermore, the absence of adequate infrastructure with sustained ultra-cold temperatures has limited the adoption of mRNA-based COVID-19 vaccines in underdeveloped countries. mRNA-based vaccines are very delicate and may easily denature and destabilize if a controlled ultra-low supply chain is not available from the time the vaccine is generated until the commencement of inoculation.
COVID-19 vaccinations based on mRNA have piqued the attention of healthcare professionals and governments because they allow the body’s own molecular mechanism to produce its own medication to combat the disease, ensuring high efficacy and safety. While mRNA-based vaccines have become a key part of vaccination regimens in affluent economies, the exorbitant expense of these vaccines is causing budgetary problems in developing countries.
Global mRNA Vaccines and Therapeutics Market Segmentation
Segmentation by Application
The market for mRNA vaccines and therapies has been divided into COVID-19 mRNA vaccines and non-COVID-19 vaccinations depending on application. The COVID-19 mRNA vaccines include include vaccinations that have been marketed as well as those that are still in development. mRNA-1273 and BNT162b2 are two marketed vaccines identified in the paper. CVnCoV, LUNAR-COV19, MRT5500, and DS-5670 are among the vaccines in the pipeline, in addition to the marketed ones.
Vaccinations for oncology, infectious disorders, and other diseases are among the non-COVID-19 vaccines. In recent months, the COVID-19 vaccine development environment has taken a favorable turn. This is due in large part to the significant efforts made by pharmaceutical firms and government entities to speed the development of COVID-19 vaccine candidates.
Segmentation by Type
According to the type of mRNA, the market for mRNA vaccines and therapeutics is classified into two categories: COVID-19 and non-COVID-19. As of Q4 2020, nucleoside-modified mRNA (modRNA) dominated the global mRNA vaccines and therapeutics market for COVID-19 vaccines, with a market share of 100%.
Segmentation by Region
The mRNA vaccines and therapeutics market is divided into five regions: North America, Europe, Asia-Pacific, Latin America, and the Rest of the World. The North American region is expected to dominate the global mRNA vaccines and therapeutics market for COVID-19 vaccines during the projected period of Q1 2021 to Q4 2025.
North America holds 54.80% of the global mRNA vaccines and therapeutics market for COVID-19 immunizations. The growing number of COVID-19 cases, the government’s increased emphasis on developing good vaccination strategies, the presence of established pharmaceutical enterprises, and higher government funding are some of the factors driving the market’s growth. Furthermore, the availability of advanced ultracold production and supply chains has substantially benefited the market’s growth in the sector.
Major Players Operating in the Global mRNA Vaccines and Therapeutics Market
Arcturus Therapeutics Holdings Inc.
Daiichi Sankyo Company, Limited.
Gennova Biopharmaceuticals Ltd
Pantherna Therapeutics GmbH
Verve Therapeutics, Inc.
mRNA Vaccines and Therapeutics Market Report
For more information, go to MarketResearch.com and get a free copy of BIS Research’s industry research, which contains key market insights. This comprehensive analysis was built using data from a number of primary and secondary sources, as well as analytical tools to develop forecast and prediction models.
Information from the publisher: BIS Research is a market intelligence, research, and consulting organization specialized in disruptive technology developments. The company’s team consists of industry veterans, experts, and analysts with experience in consulting, investment banking, government, and academia.